» Articles » PMID: 37568727

Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Aug 12
PMID 37568727
Authors
Affiliations
Soon will be listed here.
Abstract

WD40-repeat (WDR) domain proteins play a crucial role in mediating protein-protein interactions that sustain oncogenesis in human cancers. One prominent example is the interaction between the transcription factor MYC and its chromatin co-factor, WD40-repeat domain protein 5 (WDR5), which is essential for oncogenic processes. The MYC family of proteins is frequently overexpressed in various cancers and has been validated as a promising target for anticancer therapies. The recruitment of MYC to chromatin is facilitated by WDR5, highlighting the significance of their interaction. Consequently, inhibiting the MYC-WDR5 interaction has been shown to induce the regression of malignant tumors, offering an alternative approach to targeting MYC in the development of anticancer drugs. WDR5 has two protein interaction sites, the "WDR5-binding motif" (WBM) site for MYC interaction and the histone methyltransferases SET1 recognition motif "WDR5-interacting" (WIN) site forming MLL complex. Significant efforts have been dedicated to the discovery of inhibitors that target the WDR5 protein. More recently, the successful application of targeted protein degradation technology has enabled the removal of WDR5. This breakthrough has opened up new avenues for inhibiting the interaction between WDR5 and the binding partners. In this review, we address the recent progress made in targeting WDR5 to inhibit MDR5-MYC and MDR5-MLL1 interactions, including its targeted protein degradation and their potential impact on anticancer drug discovery.

Citing Articles

A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.

Ackloo S, Li F, Szewczyk M, Seitova A, Loppnau P, Zeng H J Med Chem. 2024; 68(2):1092-1112.

PMID: 39495097 PMC: 11770632. DOI: 10.1021/acs.jmedchem.4c02010.


Quantitative Hydrogen-Deuterium Exchange Mass Spectrometry for Simultaneous Structural Characterization and Affinity Indexing of Single Target Drug Candidate Libraries.

Wolf E, Herasymenko O, Kutera M, Lento C, Arrowsmith C, Ackloo S Anal Chem. 2024; 96(32):13015-13024.

PMID: 39074309 PMC: 11326436. DOI: 10.1021/acs.analchem.4c01001.


Genome-Wide Identification, Evolution, and Expression Analysis of the WD40 Subfamily in Genus.

Ke S, Jiang Y, Zhou M, Li Y Int J Mol Sci. 2023; 24(21).

PMID: 37958759 PMC: 10648978. DOI: 10.3390/ijms242115776.

References
1.
Southall S, Wong P, Odho Z, Roe S, Wilson J . Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell. 2009; 33(2):181-91. DOI: 10.1016/j.molcel.2008.12.029. View

2.
Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

3.
Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R . Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015; 11(8):571-578. PMC: 4511833. DOI: 10.1038/nchembio.1859. View

4.
Senisterra G, Wu H, Allali-Hassani A, Wasney G, Barsyte-Lovejoy D, Dombrovski L . Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J. 2012; 449(1):151-9. PMC: 3517986. DOI: 10.1042/BJ20121280. View

5.
Karatas H, Townsend E, Cao F, Chen Y, Bernard D, Liu L . High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J Am Chem Soc. 2012; 135(2):669-82. PMC: 5180416. DOI: 10.1021/ja306028q. View